Summit Therapeutics is trading 5.3% down at $16.92 on September 21, 2026, with no new company-specific announcement identified explaining the decline.
- The latest company release identified was September 15, covering updated HARMONi data presented at WCLC 2026.
- Recent analyst coverage remained constructive, including UBS’s Buy reiteration.
- Broader markets were rising, making a global risk-off explanation less convincing.